Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. Sage's lead product, designated by the U.S. Food and Drug Administration (FDA) as a breakthrough therapy for postpartum depression, was recently approved pending DEA scheduling. Sage is developing a portfolio of novel product candidates targeting critical CNS receptor systems, including SAGE-217, which is in Phase 3 development in major depressive disorder and postpartum depression.
May 23, 2019
Copyright Nasdaq. Minimum 15 minutes delayed.
Copyright West LLC. Minimum 15 minutes delayed.
Events & Presentations
May 21, 2019 at 3:35 PM EDT
RBC Capital Markets 2019 Healthcare Conference
May 14, 2019 at 11:40 AM EDT
Bank of America Merrill Lynch 2019 Health Care Conference
May 2, 2019 at 8:00 AM EDT
Sage Therapeutics Q1 2019 Financial Results Conference Call